Related Experiment Video

Updated: Jan 17, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.0K

Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease

Fernando Molina1, Alberto Mussetti2, Anna Sureda3

  • 1Bone Marrow Transplantation Unit, Hospital Británico, Buenos Aires, Argentina; Clinical Hematology Department, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona.

Haematologica
|September 25, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.0K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.1K

Related Experiment Videos

Last Updated: Jan 17, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

14.0K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

14.0K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.1K

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

886
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
886
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K

Articles linked to this work by shared authors, journal, and citation graph.

Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.

PloS one·2026

BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT.

Bone marrow transplantation·2026

GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party.

Bone marrow transplantation·2026

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article.

Bone marrow transplantation·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Cytotherapy·2026

Autoimmune and inflammatory diseases associated with T-cell clonal expansion.

Haematologica·2026

Macrophage-specific LAMTOR2 deletion disrupts systemic iron homeostasis in mice.

Haematologica·2026

Dual inhibition of JAK and MEK suppresses T-cell acute lymphoblastic leukemia induced by mutant IL7R and RASGRP1 overexpression.

Haematologica·2026

Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.

Haematologica·2026

Preserving anthracycline-containing treatment in older patients with classical Hodgkin lymphoma: a role for liposomal doxorubicin. Comment on: "Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete population".

Haematologica·2026

Mesenchymal stem cells in ribosomal insufficiency lead to aberrant osteoblastic differentiation and altered hematopoiesis.

Haematologica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us